The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
Open accessAbstract
BACKGROUND: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is unclear. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett's oesophagus. The aim of this study was to investigate whether offering this test to patients on medication for gastro-oesophageal reflux would increase the detection of Barrett's oesophagus compared with standard management. METHODS: This multicentre, pragmatic, randomised controlled trial was done in 109 socio-demographically diverse general practice clinics in England. Randomisation was done both at the general practice clinic level (cluster randomisation) and at the individual patient level, and the results for each type of randomisation were analysed separately before being combined. Patients were eligible if they were aged 50 years or older, had been taking acid-suppressants for symptoms of gastro-oesophageal reflux for more than 6 months, and had not undergone an endoscopy procedure within the past 5 years. General practice clinics were selected by the local clinical research network and invited to participate in the trial. For cluster randomisation, clinics were randomly assigned (1:1) by the trial statistician using a computer-generated randomisation sequence; for individual patient-level randomisation, patients were randomly assigned (1:1) by the general practice clinics using a centrally prepared computer-generated randomisation sequence. After randomisation, participants received either standard management of gastro-oesophageal reflux (usual care group), in which participants only received an endoscopy if required by their general practitioner, or usual care plus an offer of the Cytosponge-TFF3 procedure, with a subsequent endoscopy if the procedure identified TFF3-positive cells (intervention group). The primary outcome was the diagnosis of Barrett's oesophagus at 12 months after enrolment, expressed as a rate per 1000 person-years, in all participants in the intervention group (regardless of whether they had accepted the offer of the Cytosponge-TFF3 procedure) compared with all participants in the usual care group. Analyses were intention-to-treat. The trial is registered with the ISRCTN registry, ISRCTN68382401, and is completed. FINDINGS: Between March 20, 2017, and March 21, 2019, 113 general practice clinics were enrolled, but four clinics dropped out shortly after randomisation. Using an automated search of the electronic prescribing records of the remaining 109 clinics, we identified 13 657 eligible patients who were sent an introductory letter with 14 days to opt out. 13 514 of these patients were randomly assigned (per practice or at the individual patient level) to the usual care group (n=6531) or the intervention group (n=6983). Following randomisation, 149 (2%) of 6983 participants in the intervention group and 143 (2%) of 6531 participants in the usual care group, on further scrutiny, did not meet all eligibility criteria or withdrew from the study. Of the remaining 6834 participants in the intervention group, 2679 (39%) expressed an interest in undergoing the Cytosponge-TFF3 procedure. Of these, 1750 (65%) met all of the eligibility criteria on telephone screening and underwent the procedure. Most of these participants (1654 [95%]; median age 69 years) swallowed the Cytosponge successfully and produced a sample. 231 (3%) of 6834 participants had a positive Cytosponge-TFF3 result and were referred for an endoscopy. Patients who declined the offer of the Cytosponge-TFF3 procedure and all participants in the usual care group only had an endoscopy if deemed necessary by their general practitioner. During an average of 12 months of follow-up, 140 (2%) of 6834 participants in the intervention group and 13 (<1%) of 6388 participants in the usual care group were diagnosed with Barrett's oesophagus (absolute difference 18·3 per 1000 person-years [95% CI 14·8-21·8]; rate ratio adjusted for cluster randomisation 10·6 [95% CI 6·0-18·8], p<0·0001). Nine (<1%) of 6834 participants were diagnosed with dysplastic Barrett's oesophagus (n=4) or stage I oesophago-gastric cancer (n=5) in the intervention group, whereas no participants were diagnosed with dysplastic Barrett's oesophagus or stage I gastro-oesophageal junction cancer in the usual care group. Among 1654 participants in the intervention group who swallowed the Cytosponge device successfully, 221 (13%) underwent endoscopy after testing positive for TFF3 and 131 (8%, corresponding to 59% of those having an endoscopy) were diagnosed with Barrett's oesophagus or cancer. One patient had a detachment of the Cytosponge from the thread requiring endoscopic removal, and the most common side-effect was a sore throat in 63 (4%) of 1654 participants. INTERPRETATION: In patients with gastro-oesophageal reflux, the offer of Cytosponge-TFF3 testing results in improved detection of Barrett's oesophagus. Cyto
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,020
Locke, G., Talley, N., Fett, S., Zinsmeister, A., & Melton, L. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70025-8 · Cited by 2,095
ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus
Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.322 · Cited by 1,501
Radiofrequency Ablation in Barrett's Esophagus with Dysplasia
Shaheen, N. J., Sharma, P., Overholt, B. F., Wolfsen, H. C., Sampliner, R. E., Wang, K. K., Galanko, J. A., Bronner, M. P., Goldblum, J. R., Bennett, A. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808145 · Cited by 1,438
Fitzgerald, R. C., di Pietro, M., Ragunath, K., Ang, Y., Kang, J.-Y., Watson, P., Trudgill, N., Patel, P., Kaye, P. V., Sanders, S., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305372 · Cited by 1,346
Self-citationArnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M.-L., Myklebust, T. Å., Tervonen, H., Thursfield, V., Ransom, D., Shack, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30456-5 · Cited by 1,063
American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus
Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., & Shaheen, N. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.031 · Cited by 1,060
(2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.030 · Cited by 1,009
Banks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318126 · Cited by 647
Self-citationPhoa, K. N., van Vilsteren, F. G. I., Weusten, B. L. A. M., Bisschops, R., Schoon, E. J., Ragunath, K., Fullarton, G., Di Pietro, M., Ravi, N., Visser, M., et al. (2014) · JAMA · doi:10.1001/jama.2014.2511 · Cited by 640
Self-citation
Cited by
Morgan, E., Soerjomataram, I., Rumgay, H., Coleman, H. G., Thrift, A. P., Vignat, J., Laversanne, M., Ferlay, J., & Arnold, M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.05.054 · Cited by 1,199
Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, N. J., Falk, G. W., Iyer, P. G., Souza, R. F., Yadlapati, R. H., Sauer, B. G., & Wani, S. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001680 · Cited by 510
The future of early cancer detection
Fitzgerald, R. C., Antoniou, A. C., Fruk, L., & Rosenfeld, N. (2022) · Nature Medicine · doi:10.1038/s41591-022-01746-x · Cited by 457
Self-citationLineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Chan, J. M., Zaidi, S., Love, J. R., Zhao, J. L., Setty, M., Wadosky, K. M., Gopalan, A., Choo, Z.-N., Persad, S., Choi, J., et al. (2022) · Science · doi:10.1126/science.abn0478 · Cited by 353
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer
Thrift, A. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00419-3 · Cited by 350
Metadata
- Authors
- Fitzgerald, R. C., di Pietro, M., O'Donovan, M., Maroni, R., Muldrew, B., Debiram-Beecham, I., Gehrung, M., Offman, J., Tripathi, M., Smith, S. G., Aigret, B., Walter, F. M., Rubin, G., Bagewadi, A., Patrick, A., Shenoy, A., Redmond, A., Muddu, A., Northrop, A., Groves, A., Shiner, A., Heer, A., Takhar, A., Bowles, A., Jarman, A., Wong, A., Lucas, A., Gibbons, A., Dhar, A., Curry, A., Lalonde, A., Swinburn, A., Turner, A., Lydon, A.-M., Gunstone, A., Lee, A., Nambi, A., Ariyarathenam, A., Elden, A., Wilson, A., Donepudi, B., Campbell, B., Uszycka, B., Bowers, B., Coghill, B., de Quadros, B., Cheah, C., Bratten, C., Brown, C., Moorbey, C., Clisby, C., Gordon, C., Schramm, C., Castle, C., Newark, C., Norris, C., A'Court, C., Graham, C., Fletcher, C., Grocott, C., Rees, C., Bakker, C., Paschalides, C., Vickery, C., Schembri, D., Morris, D., Hagan, D., Cronk, D., Goddard, D., Graham, D., Phillips, D., Prabhu, D., Kejariwal, D., Garg, D., Lonsdale, D., Butterworth, D., Clements, D., Bradman, D., Blake, D., Mather, E., O'Farrell, E., Markowetz, F., Adams, F., Pesola, F., Forbes, G., Taylor, G., Collins, G., Irvine, G., Fourie, G., Doyle, H., Barnes, H., Bowyer, H., Whiting, H., Beales, I., Binnian, I., Bremner, I., Jennings, I., Troiceanu, I., Modelell, I., Emmerson, I., Ortiz, J., Lilley, J., Harvey, J., Vicars, J., Takhar, J., Larcombe, J., Bornschein, J., Aldegather, J., Johnson, J., Ducker, J., Skinner, J., Dash, J., Walsh, J., Miralles, J., Ridgway, J., Ince, J., Kennedy, J., Hampson, K., Milne, K., Ellerby, K., Priddis, K., Rainsbury, K., Powell, K., Gunner, K., Ragunath, K., Knox, K., Baseley, L., White, L., Lovat, L., Berney, L., Crockett, L., Murray, L., Westwood, L., Chalkley, L., Leggett, L., Dale, L., Scovell, L., Brooks, L., Saunders, L., Owen, L., Dilwershah, M., Baldry, M., Corcoran, M., Roy, M., Macedo, M., Attah, M., Anson, M.-J., Rutter, M., Wallard, M., Gaw, M., Hunt, M., Lea-Hagerty, M., Penacerrada, M., Bianchi, M., Baker-Moffatt, M., Czajkowski, M., Sleeth, M., Brewer, N., Wooding, N., Todd, N., Millen, N., Zolle, O., Whitehead, O., Ojechi, P., Moore, P., Banim, P., Spellar, P., Bhandari, P., Kant, P., Nixon, R., Russell, R., Roberts, R., Skule, R., West, R., Fox, R., Beesley, R., Gibbins, R., Osborne, R., Thiagarajan, S., Bastiman, S., Warburton, S., Pai, S., Leith-Russell, S., Utting, S., Watson, S., Wytrykowski, S., Singh, S., Malhotra, S., Woods, S., Conway, S., Mateer, S., Macrae, S., Singh, S., Fourie, S., Campbell, S., Parslow-Williams, S., Goel, S., Dellar, S., Jones, S., Knight, S., Mackay-Thomas, S., Mukherjee, S., Allen, S., Henry, S., Evans, T., Leighton, T., Bray, T., Shackleton, T., Santosh, V., Glover, V., Chandraraj, V., Elson, W., Briggs, W., Barron, Z., Khan, Z., & Sasieni, P.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 396
- Issue
- 10247
- Pages
- 333-344
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3046326116
- Cited by
- 261
- References
- 25
- FWCI
- 29.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31099-0
- The paper
- Fitzgerald, R. C., di Pietro, M., O'Donovan, M., Maroni, R., Muldrew, B., Debiram-Beecham, I., Gehrung, M., Offman, J., Tripathi, M., Smith, S. G., Aigret, B., Walter, F. M., Rubin, G., Bagewadi, A., Patrick, A., Shenoy, A., Redmond, A., Muddu, A., Northrop, A., . . . Sasieni, P. (2020). Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)31099-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.